Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Nuevocor logo — Pioneering novel therapies for untreatable cardiac diseases

Nuevocor

Pioneering novel therapies for untreatable cardiac diseases

Founded 2021 Singapore Singapore 29 employees Series B Total: $80.60M Biopharma, Biotechnology +1

General Information

Company Name Nuevocor
Founded Year 2021
Location Singapore Singapore
Founders / Decision Makers
Team member
Employees 29
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series B
Business Model B2B, B2B2C
Revenue Model Product Sales, Licensing, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with Nuevocor. To contact Nuevocor, visit nuevocor.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nuevocor compare?

A PDF of Nuevocor and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nuevocor soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Key Hire Oct 29, 2026

Nuevocor appointed Chris Campbell as SVP, Technical Operations, bringing over 25 years of CMC leadership.

Event Participation Oct 20, 2026

Nuevocor CEO Al Gianchetti joined Life Sciences Pennsylvania at the Pennsylvania Capitol for PA Rare Disease Day.

Nuevocor a competitor of yours? Have our desk watch it

About Nuevocor

Nuevocor, founded in 2021, is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries. With its headquarters nestled in Singapore and operational reach extending to the USA, Nuevocor is at the forefront of developing genetic medicines targeted at previously untreatable genetic cardiomyopathies.

Central to their innovation is the PrOSIA mechanobiology platform, which helps them translate cutting-edge scientific insights into viable therapies. This approach positions Nuevocor uniquely within a crucial niche market of cardiac healthcare, underscored by their slogan: "Pioneering novel therapies for untreatable cardiac diseases."

In their latest funding round on 01 May 2025, Nuevocor secured a substantial $45.00M Series B investment. Noteworthy investors include EDBI, Kurma Partners, HighLight Capital, SEEDS Capital, Angelini Ventures, Boehringer Ingelheim, and ClavystBio, underscoring strong confidence in their potential.

Business keywords: genetic medicines, cardiomyopathies, gene therapy, cardiac function restoration, PrOSIA mechanobiology platform, preclinical-stage, biopharmaceutical company, genetic cardiomyopathies, novel therapies, cardiac diseases, disease treatment

Services & Products

Development of novel therapies for cardiomyopathies
Genetic medicine research and development
Mechanobiology-centered treatment approaches

Target Customers

Patients with untreatable cardiomyopathies Healthcare providers specializing in cardiology Research institutions focusing on cardiovascular diseases

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $45.00M 7
EDBI Kurma Partners HighLight Capital
EDBI, Kurma Partners +5
01 May 2025
Early VC $11.60M 6
EDBI SEEDS Capital Boehringer Ingelheim
EDBI, SEEDS Capital +4
01 Nov 2022
Series A $24.00M 2
Boehringer Ingelheim EVX Ventures
Boehringer Ingelheim, EVX Ventures
01 Jun 2021

Nuevocor Alternatives & Competitors

View All Alternatives
Nuevocor vs
Anjarium Biosciences AG
Anjarium Biosciences AG Switzerland

DNA to Catalyze Your Advanced Therapies

Series A
15 employees
Biotechnology, Pharmaceutical
Compare Nuevocor vs Anjarium Biosciences AG
Nuevocor vs
Tenaya Therapeutics
Tenaya Therapeutics United States

Scaling new heights in the fight against heart disease

Post-IPO Equity
93 employees
Biopharma, Biotechnology
Compare Nuevocor vs Tenaya Therapeutics
Nuevocor vs
Angion
Angion United States

Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic dise...

Post-IPO Equity
19 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Nuevocor

Pioneering novel therapies for untreatable cardiac diseases
Nuevocor was founded in 2021.
Nuevocor is headquartered in Singapore.
Nuevocor operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on genetic medicines, cardiomyopathies, gene therapy and cardiac function restoration. Its customers include Patients with untreatable cardiomyopathies, Healthcare providers specializing in cardiology and Research institutions focusing on cardiovascular diseases.
Nuevocor has a B2B and B2B2C business model. Its revenue comes from Product Sales, Licensing and Value Based Pricing.
Nuevocor has approximately 29 employees.
Nuevocor has completed 3 funding rounds, raising a total of $80.60M. The latest funding stage is Series B.
Nuevocor offers: Development of novel therapies for cardiomyopathies, Genetic medicine research and development, Mechanobiology-centered treatment approaches.
Top alternatives and competitors to Nuevocor include Anjarium Biosciences AG, Tenaya Therapeutics, Angion, BreezeBio, Praxis Precision Medicines, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nuevocor and Anjarium Biosciences AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nuevocor, https://bouncewatch.com/company/nuevocor, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout